ArticleEuropean journal of heart failure2022
Impact of the COVID-19 pandemic on prescription of sacubitril/valsartan in Italy.
Article in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Observation of risk perception, knowledge and behaviour related to covid-19 in heart failure patients enrolled on a telecoaching program.BMC medical informatics and decision making · 2026Article
- Updated Trends in Valvular Heart Disease-Related Heart Failure in G20-the Group of Twenty Countries: Insights From the Global Burden of Disease Study 2021.Reviews in cardiovascular medicine · 2025Article
- Implementation of guideline-recommended medical therapy for patients with heart failure in Europe.ESC heart failure · 2025Review
- Treat or not treat COVID-19 with combined renin-angiotensin system and neprilysin inhibition: Have we found a solution?European journal of heart failure · 2025Article
- Cause-Specific Excess Mortality During the COVID-19 Pandemic (2020-2021) in 12 Countries of the C-MOR Consortium.Journal of epidemiology and global health · 2024Article
- Impact of the COVID-19 pandemic on implementation of novel guideline-directed medical therapies for heart failure in Germany: a nationwide retrospective analysis.The Lancet regional health. Europe · 2023Article
- Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.The Lancet regional health. Europe · 2023Article
- Corrigendum to: 'An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum' and articles listed below.European journal of heart failure · 2023Article
- Frequency and Type of Outpatient Visits for Patients With Cardiovascular Ambulatory-Care Sensitive Conditions During the COVID-19 Pandemic and Subsequent Outcomes: A Retrospective Cohort Study.Journal of the American Heart Association · 2023Article
- Virtual Outpatient Visits During COVID-19 Pandemic: So Distant, Yet So Close.Journal of the American Heart Association · 2023Article
- The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network.International journal of cardiology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe present study sought to examine the effect of the COVID-19 pandemic and lockdown measures on the prescription of sacubitril/valsartan in patients with heart failure (HF) in Italy. METHODS AND
resultsData from Italian Medicines Agency (AIFA) monitoring registries were analysed. The sacubitril/valsartan monitoring registry is based on 6-month prescriptions. A monthly aggregation on new activations throughout the observational period was computed. From March to December 2020, the initiation of new HF patients on sacubitril/valsartan decreased by nearly 40% with prescriptions dropping to values similar to 2018 when the registry was still operated off-line. A slight increase in prescriptions was observed after the lockdown measures were lifted, but prescriptions remained constantly below the pre-lockdown period.
conclusionA marked and worrisome decline during the COVID-19 pandemic in the activation of a life-saving treatment such as sacubitril/valsartan was observed. This decline was clearly linked to the lockdown measures instated to counteract the COVID-19 pandemic. Upcoming studies should analyse the occurrence of new cases of HF as well as the severity of patients admitted to hospitals and their mortality compared to pre-pandemic levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.